A reduced rate of glioblastoma and ovarian tumour progression was observed when the respective cancer cells were pretreated with PAM/CP prior to xenografting, with immunohistochemical analysis showing increased p38, JNK, and caspase 3 activation in CP-treated tumours [147,232]. The gene discussed is CASP3; the disease is cancer.